Verve Therapeutics Inc
NASDAQ:VERV

Watchlist Manager
Verve Therapeutics Inc Logo
Verve Therapeutics Inc
NASDAQ:VERV
Watchlist
Price: 6.16 USD -2.53% Market Closed
Market Cap: 549.1m USD

Wall Street
Price Targets

VERV Price Targets Summary
Verve Therapeutics Inc

Wall Street analysts forecast VERV stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for VERV is 25.67 USD with a low forecast of 15.15 USD and a high forecast of 40.95 USD.

Lowest
Price Target
15.15 USD
146% Upside
Average
Price Target
25.67 USD
317% Upside
Highest
Price Target
40.95 USD
565% Upside
Verve Therapeutics Inc Competitors:
Price Targets
ONCO
Oncopeptides AB
294% Upside
TSHA
Taysha Gene Therapies Inc
187% Upside
BPMC
Blueprint Medicines Corp
0% Downside
300685
Amoy Diagnostics Co Ltd
43% Upside
1167
Jacobio Pharmaceuticals Group Co Ltd
60% Downside
300142
Walvax Biotechnology Co Ltd
10% Downside
TRDA
Entrada Therapeutics Inc
218% Upside
BNTX
BioNTech SE
26% Upside

Revenue
Forecast

Revenue Estimate
Verve Therapeutics Inc

The compound annual growth rate of Verve Therapeutics Inc's revenue for the next 3 years is -24%.

N/A
Past Growth
-24%
Estimated Growth
Estimates Accuracy
51%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Verve Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Net Income
Forecast

Net Income Estimate
Verve Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-38%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is VERV's stock price target?
Price Target
25.67 USD

According to Wall Street analysts, the average 1-year price target for VERV is 25.67 USD with a low forecast of 15.15 USD and a high forecast of 40.95 USD.

What is Verve Therapeutics Inc's Revenue forecast?
Projected CAGR
-24%

The compound annual growth rate of Verve Therapeutics Inc's revenue for the next 3 years is -24%.

Back to Top